|
InvivoSciences is a provider in ready-to-use engineered tissues and their assay
platforms. Our products and services provide unique solutions to reduce the
cost and time in animal studies in academic and drug discovery laboratories.
The assay platform can be used to screen toxic compounds that affect a
structural integrity on cell’s cytoskeleton (skeleton of cells that gives a
cell its structural support), and to profile potentially effective compounds in
wound healing and heart diseases.
Our R&D effort is focused on developing an assay system to screen and profile
drug candidates against cardiac fibrosis. The rise of heart attack cases is so
rapid; recently one million cases per year have been reached in US. The heart attack injures heart muscles and
forms wounds. Wounded heart muscles almost
never heal properly, leave scar tissues and develop cardiac fibrosis. Due to the scar expansion, many of survivors who
had the attack (~38%) will die within one year.
Although the fibrosis is a significant risk factor associated with
altered mechanical performance of hearts and arrhythmogenesis, almost no
therapeutics target cardiac fibrosis. Reversing
the fibrosis is a critical, yet unmet need for patients who survived heart
attack.
The technologies being developed by IVS will
be designed to assist academic laboratories and pharmaceutical companies identify
drug candidates that 1) protect heart muscle from heart attacks by minimize the
damage and 2) slow down wound expansion or reverse fibrosis.
|
